Anzeige
❌
Mehr »
Dienstag, 10.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 1,42 USD bis Juni 2027, die 200 % Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAGC | ISIN: DK0060448595 | Ticker-Symbol: CBHD
Tradegate
10.11.26 | 14:30
66,04 Euro
-2,05 % -1,38
1-Jahres-Chart
COLOPLAST A/S Chart 1 Jahr
5-Tage-Chart
COLOPLAST A/S 5-Tage-Chart
RealtimeGeldBriefZeit
65,8666,0614:32
66,0266,0814:31

Aktuelle News zur COLOPLAST Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrColoplast A/S: Notice of Annual General Meeting 20266
DoColoplast: Mehr Umsatz, weniger Gewinn - Aktie legt zu17
MiBarclays upgrades Coloplast stock rating on growth outlook28
MiColoplast Q4 Profit Up 36%; Revenue Rises 7%; Guides FY27430BRUSSELS (dpa-AFX) - Coloplast A/S (COLO-B.CO, CLPBY, COLOb.CO), a Danish medical devices manufacturer, Wednesday said that its fourth-quarter profit rose 36 percent, helped by good performance...
► Artikel lesen
03.11.Coloplast A/S reports revised financial ambition towards 2030 and FY 2026/27 guidance16
03.11.Coloplast FY 2025/26 slides: 6% growth amid margin pressure, 2030 ambition revised34
COLOPLAST Aktie jetzt für 0€ handeln
03.11.Coloplast verfehlt EPS-Erwartungen im vierten Quartal - Aktie verliert nach gesenktem Ausblick 2,7 %47
03.11.Coloplast A/S: Coloplast A/S - Annual Report 2025/26 & Remuneration Report 2025/26383FY 2025/26 organic growth was 6% and EBIT growth1 in constant currencies was 4%. Reported revenue in DKK grew 4%, reflecting 2%-points negative impact from currencies. Organic growth rates by business...
► Artikel lesen
03.11.3 Funktionen, die Patienten zurückwollen: Was Coloplasts, Boston Scientifics und NurExones Tierdaten zeigen
02.11.Coloplast A/S: Coloplast A/S Announcement no. 11/2026 - 2025/26 Full-Year Financial Results2481 October 2025 - 30 September 2026 Coloplast delivered 5% organic growth in Q4, driven by continued strength in Chronic Care and Interventional Urology. EBIT growth1 in constant currencies was 0% and...
► Artikel lesen
02.11.Coloplast A/S: Coloplast A/S Announcement no. 10/2026 - Coloplast announces revised financial ambition towards 2030 and FY 2026/27 guidance407Announcement no. 10/2026Inside information Revised financial ambition towards 2030 includes 5-7% organic growth per year and an EBIT margin1 in constant currencies in the mid-20% range over the period....
► Artikel lesen
29.10.Coloplast A/S: Coloplast opens new factory in Portugal to support global growth535Coloplast today inaugurates its largest manufacturing site to date, a two-floor 50,000 m2 facility in Felgueiras, Portugal, expanding the company's production capacity to meet growing global demand...
► Artikel lesen
01.10.Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons38
01.10.Coloplast A/S - Major shareholder announcement39
24.09.Coloplast A/S - Financial Calendar 2026/2725
10.09.Ist die Coloplast-Aktie nach den Kursverlusten ein Kaufkandidat?104
09.09.Bewertung zu hoch: JPMorgan stuft Coloplast Aktie herab131
09.09.JPMorgan downgrades Coloplast stock rating on valuation concerns42
04.09.Coloplast A/S: Supporting the continued long-term and stable ownership of Coloplast802Coloplast has been informed that the Danish Financial Supervisory Authority (FSA) has today announced that it has notified Niels Peter Louis-Hansen that it has granted an exemption from the obligation...
► Artikel lesen
02.09.CEO-Wechsel bei Coloplast: Morgan Stanley hebt Rating an70
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,11